Century Therapeutics (IPSC) Status Update summary

Strategic pipeline reprioritization and platform advantages

• Four transformative preclinical programs prioritized, all leveraging Allo-Evasion 5.0 technology for enhanced immune evasion and persistence.

• iPSC-derived therapies offer engineerability, reproducibility, and scalable manufacturing, aiming for antibody-like production costs and broad patient access.

• Proprietary Allo-Evasion 5.0 includes pan-NK inhibition (CD300a), IgG degrading protease, and HLA class I/II ablation, providing comprehensive protection from immune rejection.

• Century's iPSC platform enables creation of multiple cell types with Allo-Evasion™ technology for immune evasion.

• Manufacturing facility enables integrated development, rapid process iteration, and protection of proprietary know-how, supporting large-scale production.

Program highlights and clinical development

• CNTY-308, an iPSC-derived αβ T cell product with CD19 CAR, is advancing toward IND-enabling studies mid-year, targeting both oncology and autoimmune indications.

• CNTY-341 features a dual-targeting CAR (CD19/CD22) to address antigen loss in lymphoma, using a proprietary CD22 binder for improved efficacy.

• Solid tumor pipeline includes Nectin-4, GPC3, CD70, and mesothelin CARs, with additional edits for enhanced tumor microenvironment resistance and persistence.

• Non-immune effector cell program is in development, leveraging iPSC technology for regenerative medicine applications.

• CNTY-101 (iNK, Allo-Evasion™ 1.0) is advancing for autoimmune diseases, with the CARAMEL trial expected to start mid-2025.

Manufacturing and scalability

• Master cell banks established for key programs, enabling unlimited batch sizes and consistent product quality.

• Dynamic bioreactor systems allow for large-scale, cost-effective production, with current facility capacity to treat thousands of patients annually.

• Century operates a 53,000 ft² cGMP facility with in-house and CDMO manufacturing options for flexibility and risk mitigation.

• Cost of goods already lower than autologous therapies, with further reductions expected as scale increases.

• Manufacturing development supports scalable, dynamic cell production systems aiming for antibody-like cost and scale.